Genmab’s Tisotumab Vedotin Study: A Potential Game-Changer in Cancer Treatment

Genmab (Otc) ((GMAB)) announced an update on their ongoing clinical study.

Genmab, in collaboration with Seagen and Merck Sharp & Dohme, is conducting an open-label Phase 2 study titled ‘Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors.’ The study aims to assess the effectiveness and safety of tisotumab vedotin, alone or in combination with other anticancer drugs, for treating various solid tumors. This research is significant as it explores new treatment avenues for challenging cancer types, potentially improving patient outcomes.

The intervention being tested is tisotumab vedotin, a drug administered intravenously. It is being evaluated both as a standalone treatment and in combination with other drugs like pembrolizumab, carboplatin, and cisplatin, targeting solid tumors such as colorectal cancer and head and neck squamous cell carcinoma.

The study design is interventional, non-randomized, and follows a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. The study includes multiple parts, each testing different schedules and combinations of the drug.

The study began on June 25, 2018, with its primary completion and estimated completion dates not yet specified. The most recent update was submitted on August 11, 2025. These timelines are crucial for tracking the study’s progress and anticipating when results might influence clinical practices and market dynamics.

This study update could impact Genmab’s stock performance and investor sentiment positively if the results show promising efficacy and safety profiles. It positions Genmab competitively within the oncology sector, especially against other companies developing similar therapies.

The study remains active but is not recruiting new participants. Further details are available on the ClinicalTrials portal.